Clinical Trial Detail

NCT ID NCT01326702
Title Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoma

Advanced Solid Tumor

multiple myeloma

Therapies

Veliparib

Rituximab

Bendamustine

Age Groups: adult senior

No variant requirements are available.